Human medicines European public assessment report (EPAR): Zubsolv, buprenorphine,naloxone, Opioid-Related Disorders, Date of authorisation: 10/11/2017, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Zubsolv, buprenorphine,naloxone, Opioid-Related Disorders, Date of authorisation: 10/11/2017, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Esophageal Squamous Cell Carcinoma, Date of authorisation: 15/09/2023, Status: Authorised

Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Esophageal Squamous Cell Carcinoma, Date of authorisation: 15/09/2023, Status: Authorised

Human medicines European public assessment report (EPAR): Dupixent, dupilumab, Dermatitis, Atopic;Prurigo;Esophageal Diseases;Asthma;Sinusitis, Date of authorisation: 26/09/2017, Revision: 30, Status: Authorised

Human medicines European public assessment report (EPAR): Dupixent, dupilumab, Dermatitis, Atopic;Prurigo;Esophageal Diseases;Asthma;Sinusitis, Date of authorisation: 26/09/2017, Revision: 30, Status: Authorised

Human medicines European public assessment report (EPAR): Reblozyl, luspatercept, Anemia;Myelodysplastic Syndromes;beta-Thalassemia, Date of authorisation: 25/06/2020, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Reblozyl, luspatercept, Anemia;Myelodysplastic Syndromes;beta-Thalassemia, Date of authorisation: 25/06/2020, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Tezspire, tezepelumab, Asthma, Date of authorisation: 19/09/2022, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Tezspire, tezepelumab, Asthma, Date of authorisation: 19/09/2022, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Bortezomib Hospira, bortezomib, Multiple Myeloma, Date of authorisation: 22/07/2016, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Bortezomib Hospira, bortezomib, Multiple Myeloma, Date of authorisation: 22/07/2016, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Rybelsus, semaglutide, Diabetes Mellitus, Type 2, Date of authorisation: 03/04/2020, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Rybelsus, semaglutide, Diabetes Mellitus, Type 2, Date of authorisation: 03/04/2020, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Lucentis, ranibizumab, Wet Macular Degeneration;Macular Edema;Diabetes Complications;Myopia, Degenerative, Date of authorisation: 22/01/2007, Revision: 43, Status: Authorised

Human medicines European public assessment report (EPAR): Lucentis, ranibizumab, Wet Macular Degeneration;Macular Edema;Diabetes Complications;Myopia, Degenerative, Date of authorisation: 22/01/2007, Revision: 43, Status: Authorised

Human medicines European public assessment report (EPAR): GONAL-f, follitropin alfa, Anovulation;Reproductive Techniques, Assisted;Infertility, Female;Hypogonadism, Date of authorisation: 20/10/1995, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): GONAL-f, follitropin alfa, Anovulation;Reproductive Techniques, Assisted;Infertility, Female;Hypogonadism, Date of authorisation: 20/10/1995, Revision: 26, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness